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ABSTRACT
Objectives Patients with suspected acute coronary 
syndrome and high- sensitivity cardiac troponin (hs- cTn) 
concentrations below the limit of detection at presentation 
are low risk. We aim to determine whether implementing 
this approach facilitates the safe early discharge of 
patients.
Methods In a prospective single- centre cohort study, 
consecutive patients with suspected acute coronary 
syndrome were included before (standard care) and 
after (intervention) implementation of an early rule- out 
pathway. During standard care, myocardial infarction 
was ruled out if hs- cTnT concentrations were <99th 
centile (14 ng/L) at presentation and at 6–12 hours after 
symptom onset. In the intervention, patients were ruled out 
if hs- cTnT concentrations were <5 ng/L at presentation 
and symptoms present for ≥3 hours or were ≥5 ng/L and 
unchanged within the reference range at 3 hours. We 
compared duration of stay (efficacy) and all- cause death at 
1 year (safety) before and after implementation.
Results We included 10 315 consecutive patients (64±16 
years, 46% women) with 6642 (64%) and 3673 (36%) in 
the standard care and intervention groups, respectively. 
Duration of stay was reduced from 534 (IQR, 220–2279) to 
390 (IQR, 218–1910) min (p<0.001) after implementation. 
At 1 year, all- cause death occurred in 10.9% (721 of 6642) 
and 10.4% (381 of 3673) of patients in the standard 
care group (referent) and intervention group, respectively 
(adjusted OR 1.02, 95% CI 0.88 to 1.18).
Conclusion In patients with suspected acute coronary 
syndrome, implementing an early rule- out pathway using 
hs- cTnT concentrations <5 ng/L at presentation reduced 
the duration of stay in hospital without compromising 
safety.
INTRODUCTION
Chest pain is a common presentation and 
is responsible for approximately 700 000 
hospital admissions per annum in the UK 
alone.1 Given that the majority of patients 
with chest pain do not have acute myocardial 
infarction, strategies that safely identify low- 
risk patients in the emergency department 
and reduce the need for hospital admission 
would be of major benefit to both patients 
and healthcare providers.
High- sensitivity cardiac troponin (hs- cTn) 
is the gold standard biomarker for diag-
nosis of myocardial infarction.2 The Fourth 
Universal Definition of Myocardial Infarction 
Key questions
What is already known about this subject?
 ► Cardiac troponin using high- sensitivity assays can 
accurately risk stratify patients with suspected 
acute coronary syndrome.
 ► The use of early rule- out pathways using high- 
sensitivity cardiac troponin (hs- cTn) has been rec-
ommended by European Society of Cardiology for 
patients with suspected myocardial infarction.
What does this study add?
 ► We show that the implementation of an early rule- 
out pathway, using an hs- cTnT assay, reduces dura-
tion of stay in hospital without compromising safety 
in a large, unselected and consecutive cohort of over 
10 000 patients presenting with suspected acute 
coronary syndrome.
How might this impact on clinical practice?
 ► In patients with suspected acute coronary syn-
drome, implementing an early rule- out pathway, 
using an hs- cTnT concentration of <5 ng/L at pre-
sentation for risk stratification, reduced the duration 
of stay in hospital without compromising safety.
 ► The adoption of this approach in clinical practice 
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requires a rise and/or fall in cardiac troponin concentra-
tions above the 99th percentile to confirm the diagnosis.2 
Previous studies have demonstrated that troponin concen-
trations below the limit of detection have a high negative 
predictive value and sensitivity to rule out myocardial 
infarction3–7 and these patients remain at low risk.5 8–11 
Improved sensitivity of cardiac troponin assays has there-
fore enabled the development of multiple early rule- out 
pathways.11–15 Most studies evaluating early rule- out path-
ways have been observational in nature, combining the 
limit of detection with electrocardiographic criteria or 
risk scores.6 16 While a single measurement at presenta-
tion is more cost- effective than delayed testing,5 the clin-
ical effectiveness and safety of this approach in practice 
remains uncertain.17
We have evaluated the efficacy and safety of imple-
menting an early rule- out pathway using an hs- cTnT 
concentration <5 ng/L at presentation to risk stratify 
patients with suspected acute coronary syndrome.
METHODS
Study design and participants
In this prospective single centre, controlled before 
and after study, we included consecutive patients with 
suspected acute coronary syndrome presenting to a 
secondary care hospital, the Victoria Hospital in Kirk-
caldy, Scotland, between 25 November 2014 and 12 June 
2017, in whom the attending clinician measured hs- cTnT. 
The hs- cTnT assay was introduced in our hospital on 
25 November 2014. An early rule- out pathway using an 
hs- cTnT concentration of <5 ng/L at presentation to rule 
out myocardial infarction was introduced on 13 June 
2016. Patients were excluded if they were not residents 
in Scotland, had a previous presentation during the study 
period or had an ST- segment elevation myocardial infarc-
tion as these patients were taken directly to a regional 
cardiac centre for primary percutaneous coronary inter-
vention. All patients who had an hs- cTnT measurement 
on presentation to hospital since the introduction of the 
assay were included in the study.
Data collection and record linkage were performed 
with permission from the National Health Service (NHS) 
Caldicott Guardian. Individual patient consent was not 
sought as all data were routinely collected from the 
electronic patient record with no additional research 
procedures. Data were prospectively collected, de- iden-
tified, linked within a secure NHS safe haven. This study 
was conducted in accordance with the Declaration of 
Helsinki.
Patient and public involvement
No patients were involved in setting the research ques-
tion or the endpoint measures, nor were they involved in 
developing plans for design of the study. No patients were 
asked to advise on interpretation or writing up of results.
Cardiac troponin assay and pathways
Throughout the study, hs- cTnT was measured on the 
Cobas e602 platform (Roche Diagnostics, Basal, Switzer-
land) which has a manufacture- specified limit of detec-
tion of 3 ng/L on this platform and a non- sex- specific 
99th percentile upper reference limit of 14 ng/L.18
Patients with suspected acute coronary syndrome were 
included before (standard care) and after (intervention) 
implementation of the early rule- out pathway. During stan-
dard care, patients had troponin measured at presentation 
and a repeat measurement at 6 or 12 hours from symptom 
onset in those considered low (<1% death at 6 months) 
and high risk (≥1% death at 6 months) according to the 
GRACE score (figure 1).19 During the implementation 
period, patients with undetectable hs- cTnT concentrations 
(<5 ng/L) and symptoms >3 hours at presentation were iden-
tified as low risk and considered for immediate discharge. In 
Figure 1 Standard care and intervention pathways flow chart showing the pathway used in the standard care and intervention 
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patients presenting within 3 hours of symptom onset or those 
with hs- cTnT concentrations within the reference range 
from 5 to 14 ng/L, testing was repeated 3 hours from presen-
tation and those without a significant change (<3 ng/L at 
3 hours) were identified as low risk and considered for early 
discharge.20
During both phases, myocardial infarction was consid-
ered in patients with an hs- cTnT concentration >14 ng/L 
and an absolute change of ≥10 ng/L following repeat 
testing based on previous research with this assay.21 In the 
3 months prior to implementation of the early rule- out 
pathway, regular educational presentations, as well as 
written and online materials, were provided to clinical 
staff. While clinical staff were encouraged to follow the 
early rule- out pathway, the final diagnosis and manage-
ment during the entire study period were at the discre-
tion of the treating clinician.
Efficacy and safety endpoints
The primary efficacy endpoint was duration of hospital 
stay. The secondary efficacy endpoint was the proportion of 
patients discharged from hospital at 4 hours. The primary 
safety endpoint was all- cause death at 1 year. Secondary safety 
endpoints were all- cause death at 30 days and cardiovascular 
death at 30 days and 1 year. Information on cause of death 
was obtained using the NHS Central Register as previously 
described.22 Cardiovascular death was classified using the 
10th revision of the International Classification of Diseases 
(ICD- 10), and defined with ICD- 10 codes (myocardial infarc-
tion=I21, I22; cerebrovascular disease=I60, I61, I63–66; heart 
failure=I110, I130, I1426, I50).
Statistical analysis
We compared standard care and intervention in all patients 
with suspected acute coronary syndrome and stratified 
by hs- cTnT concentrations at presentation (<5 ng/L, 
between 5 and 14 ng/L, and >14 ng/L) (figure 1). For 
comparisons, we used the Student’s t- test and Mann- 
Whitney U test for normally and non- normally distrib-
uted continuous variables, respectively. Χ2 test was used 
for categorical variables. To evaluate the primary efficacy 
endpoint, we used linear regression to compare the dura-
tion of stay (natural log) between standard care and the 
intervention (reference=standard care), adjusted for age, 
sex, creatinine, diabetes mellitus, and prior myocardial 
infarction, heart failure or cerebrovascular disease. The 
primary and secondary safety endpoints were compared 
between the standard care and intervention groups using 
logistic regression in unadjusted (model 1) and then 
adjusted models for age, sex, renal function and comor-
bidity. Sample size calculations were performed using 
the duration of hospital stay as the primary endpoint. As 
duration of stay is non- normally distributed, a sample size 
calculation was done based on the approach by O’Keeffe 
et al.23 A sample size of 2503 patients in each group would 
give 90% power at an alpha of 0.05 for detecting a 20% 
difference in median duration of stay, where the duration 
of stay in the standard care group was 530 min. Statistical 
analyses were carried out using R V.3.6.3 (R Foundation 
for Statistical Computing, Vienna, Austria).
Data availability statement
This study makes use of multiple routine electronic 
healthcare data sources that are linked, de- identified and 
held in our safe haven, which are accessible by approved 
individuals who have undertaken the necessary govern-
ance training. Summary data can be made available upon 
request to the corresponding author.
RESULTS
Clinical characteristics of study population
We included 10 315 consecutive patients (54% men, 
mean age 64 years) with suspected acute coronary 
syndrome (table 1). Of these, 6642 (64%) patients were 
in the standard care group and 3673 (36%) patients were 
in the intervention group (figure 1). Mean age and sex 
were similar in both groups. The intervention group 
was less likely to have a history of myocardial infarction 
(7.6% vs 4.2%) or heart failure (4.7% vs 3.2%). In the 
standard care group (6642), the number and proportion 
of patients with hs- cTnT concentration <5 ng/L, between 
5 and 14 ng/L, and >14 ng/L were 2188 (32.9%), 1885 
(28.4%), and 2569 (38.7%), respectively. In the inter-
vention group (3673), the number and proportion of 
patients with hs- cTnT <5 ng/L, between 5 and 14 ng/L, 
and >14 ng/L were 945 (25.7%), 1380 (37.6%), and 1348 
(36.7%), respectively.
Efficacy of implementing the early rule-out pathway
In the overall study population, the primary efficacy 
endpoint of duration of stay was lower after implementa-
tion of the early rule- out pathway (534 (IQR, 220–2279) 
vs 390 (IQR, 218–1910) min, p<0.001; table 1). In patients 
with hs- cTnT concentrations below 5 ng/L at presenta-
tion, the duration of stay was reduced from 236 (IQR, 
180–484) min to 219 (IQR, 170–328) min (p<0.001, 
figure 2) following implementation of the early rule- out 
pathway. The reduction in duration of stay from the 
start to the end of intervention was consistent over time 
(online supplemental figure 1). In patients with hs- cTnT 
concentrations between 5 and 14 ng/L, the duration 
of stay was also reduced following implementation 
(421 (IQR, 215–1214) min vs 311 (IQR, 215–838) min, 
p<0.001). The reduction in duration of stay was seen in 
all patients with hs- cTnT concentrations below the diag-
nostic threshold (<14 ng/L) (295 vs 255 min) (online 
supplemental table 1). However, there was no reduction 
in duration of stay in those patients with an hs- cTnT 
concentration >14 ng/L (2259 (IQR, 665–6054) min vs 
2567 (IQR, 688–6191) min, p=0.363). This observation 
remained consistent following adjustment for age, sex 
and comorbidity (online supplemental table 2).
The secondary efficacy endpoint of the proportion of 
patients discharged from hospital at 4 hours was higher 
in the intervention group compared with the standard 






ber 16, 2021 at T











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ber 16, 2021 at T













5Sandeman D, et al. Open Heart 2021;8:e001769. doi:10.1136/openhrt-2021-001769
Coronary artery disease
greatest increase was in patients with troponin concentra-
tions <5 ng/L at presentation (63.9% vs 52.5%, p<0.001; 
figure 3). There was no statistically significant difference 
in 1- year mortality in those patients <5 ng/L who were 
discharged <4 or >4 hours from presentation (2 of 604 
(0.3%) vs 3 of 341 (0.6%), p=0.953).
Safety of implementing the early rule-out pathway
A total of 1102 (10.7%) patients died within 1 year 
(table 1). At 1 year, 10.9% and 10.4% of patients had died 
before and after implementation of the early rule- out 
pathway, respectively. Compared with those patients in 
standard care, there was no statistically significant differ-
ence in all- cause death at 1 year following implementation 
of the early rule- out pathway after adjustment for age, 
sex, diabetes, creatinine, previous myocardial infarction, 
heart failure or cerebrovascular disease (OR 1.02, 95% CI 
0.88 to 1.18, figure 4). In patients with troponin concen-
trations <5 ng/L at presentation, 0.8% (17 of 2188) and 
0.4% (4 of 945) died before and after implementation 
of the early rule- out pathway (adjusted OR 0.59, 95% CI 
0.19 to 1.47, p=0.291). In patients with troponin concen-
trations between 5 and 14 ng/L, all- cause death at 1 year 
occurred in 3.9% and 3.5% before and after implemen-
tation of the early rule- out pathways (adjusted OR 0.96, 
95% CI 0.65 to 1.41, p=0.839).
Consistent with the primary safety endpoint, there was 
no statistically significant difference in cardiovascular 
death at 1 year before and after implementation in all 
patients with suspected acute coronary syndrome (5.5% 
vs 5.6%, adjusted OR 1.13, 95% CI 0.93 to 1.36, p=0.221; 
table 1) or in those with troponin concentrations <5 ng/L 
(0.2% vs 0.1%, adjusted OR 1.18, 95% CI 0.16 to 6.20, 
p=0.853), and between 5 and 14 ng/L (1.1% vs 1.2%, 
adjusted OR 1.19, 95% CI 0.60 to 2.33, p=0.614). We 








































































































































































































































































































































































































Figure 2 Duration of stay. Density plot illustrating the 
duration of hospital stay for the standard care (grey) 
and intervention (yellow) groups stratified according 
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in all- cause death and cardiovascular death at 30 days 
between the standard care and intervention groups 
(online supplemental table 1).
DISCUSSION
In a large cohort of 10 315 consecutive patients with 
suspected acute coronary syndrome, we evaluated the 
effectiveness and safety of implementing an early rule- out 
pathway using an hs- cTnT concentration of <5 ng/L to 
risk stratify patients at presentation. Implementation of 
this approach was associated with a reduction in the dura-
tion of hospital stay and an increase in the proportion of 
patients discharged directly from the emergency depart-
ment. This was achieved without any change in all- cause 
or cardiovascular deaths at 1 year, suggesting that the use 
of this approach to risk stratify patients with suspected 
acute coronary syndrome is both safe and effective in 
routine clinical practice.
There are several strengths to our study. First, our 
before and after study, unlike an individual patient- level 
randomised controlled trial, enables inclusion of consec-
utive patients regardless of age, sex, symptoms, time of 
presentation or comorbidities. Using such an approach 
limits selection bias and improves the generalisability of 
our findings. Implementation at the hospital level mini-
mised the risk of a Hawthorn effect from researchers 
observing care, which may exaggerate the effectiveness 
of implementing early rule- out pathways. Second, we 
included a large population of 10 315 patients in the 
study with over 1000 deaths. We are not aware of any 
other prospective study of this size evaluating the imple-
mentation of an early rule- out pathway using hs- cTnT. 
Third, given the robust national databases available in 
Scotland, which have already been used to deliver longi-
tudinal cohort studies and randomised controlled trials, 
we were able to evaluate the short- term and long- term 
impact of implementing an early rule- out pathway with 
all- cause mortality as our primary safety outcome and 
complete follow- up.22 24 25 This approach limits misclas-
sification bias and we further presented cause- specific 
mortality evaluating cardiovascular deaths.
Our analysis showed that the implementation of an 
early rule- out pathway led to substantial reductions in the 
duration of stay in hospital. This observation was likely 
due to both a change in the threshold for ruling out 
myocardial infarction and reducing the timing between 
serial sampling. However, not all patients with an initial 
troponin concentration <5 ng/L on presentation were 
discharged according to the pathway. This may be due 
to ongoing symptoms, early presentations (<3 hours), or 
other medical and social reasons requiring hospitalisa-
tion. Our findings extend the current literature. Using 
a high- sensitivity troponin I assay, the High- Sensitivity 
cardiac Troponin On presentation to Rule out myocar-
dial InfarCtion trial demonstrated that implementation 
of an early rule- out pathway reduced duration of stay 
by 3.3 hours with no increase in 1- year mortality using 
a stepped- wedge cluster randomised design in 31 492 
Figure 3 Discharge at 4 hours. Proportion of patients discharged within 4 hours (green) and after 4 hours (grey) before (A) 
and after (B) implementation of early rule- out pathway stratified according to presentation high- sensitivity cardiac troponin T 
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patients.26 In contrast, the Limit of Detection and ECG 
Discharge trial showed that implementing an early 
rule- out pathway using the limit of detection of a range 
of hs- cTn assays when combined with a normal ECG 
increased 4- hour discharge rates, but did not significantly 
reduce duration of stay and the trial was not powered 
to evaluate safety outcomes.16 The Rapid Assessment of 
Possible acute coronary syndrome In the Emergency 
Department with high- sensitivity TnT trial compared a 
1- hour pathway that incorporates the limit of detection 
with a 3- hour rule- out pathway using the 99th centile 
in 3378 patients, and reported that the 1- hour strategy 
reduced duration of stay by 60 min and increased 
discharge rates from 32% to 45%.27 The trial concluded 
non- inferiority for a composite primary endpoint that 
included index events, but there were only 6 deaths at 
30 days. However, follow- up at 1 year demonstrated an 
increase in both subsequent myocardial infarction and 
death in patients with low troponin concentrations iden-
tified by the hs- cTnT assay and randomised to the 1- hour 
strategy compared with the 3- hour pathway using the 
99th centile.28 The explanation for these unexpected 
findings is not clear, but they highlight the importance 
of conducting adequately powered studies that evaluate 
both the effectiveness and safety of implementing early 
rule- out pathways. Furthermore, one other before and 
after study has evaluated the implementation of an early 
rule out pathway with hs- cTnT demonstrating a reduc-
tion in hospital admissions with no excess in adverse 
events.29 However, this study evaluated the HEART score 
and a change in hs- cTnT of <3 ng/L to identify low- risk 
patients.
In our study, implementation of an early rule- out 
pathway using hs- cTnT reduced duration of stay and was 
not associated with any change in all- cause or cardiovas-
cular mortality at 1 year. The biggest reduction was seen 
in the 5–14 ng/L group which likely reflects the change 
in timing of serial sample from 6 or 12 hours to 3 hours. 
There was no evidence of harm in models adjusting for 
age, sex and comorbidity. Studies that have evaluated 
early rule- out pathways have primarily looked at short- 
term outcomes with small number of fatal or non- fatal 
events16 or have evaluated hs- cTnI assays.30 We assessed 
safety using both short- term and long- term outcomes. 
Across the study cohort, we had over 1000 deaths and 
showed, with a significant degree of confidence, that 
those patients managed with an early rule- out pathway 
were not at higher risk overall or when stratified according 
to hs- cTnT concentration at presentation.
Our pathway was based on the High- STEACS early 
rule- out pathway20 31 32 developed using an hs- cTnI assay. 
Our study therefore has important clinical implications 
providing further confidence in early rule- out pathways 
using a hs- cTnT assay. The findings from our study add 
Figure 4 Outcomes. All- cause death at 1 year in all patients admitted following implementation of an early rule- out pathway 
compared with standard care, and stratified by troponin concentrations at presentation <5 ng/L, between 5 and 14 ng/L, and 
>14 ng/L. Model 1=crude unadjusted model; model 2=model 1+age+sex; model 3=model 2+sex, creatinine, diabetes mellitus, 
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to a recently published systematic review of 37 studies 
evaluating the diagnostic performance of two- step hs- cTn 
pathways.33 This evidence review informed the National 
Institute for Health and Care Excellence guideline, which 
recommended pathways using hs- cTn concentrations 
near the limit of detection at presentation as a first step 
with a second step of small absolute changes to safely rule 
out myocardial infarction.34 This concept is also recom-
mended by the European Society of Cardiology guide-
lines using a rule- out threshold of <5 ng/L and a change 
of <3 ng/L in 0/1- hour or 0/2- hour pathways based on 
these principles.35 Our findings should provide clinicians 
with additional confidence when adopting early rule- out 
pathways into clinical practice.
Study limitations
First, this was a single- centre study in a large secondary 
care hospital in Scotland, and the impact of adopting this 
approach may differ in tertiary referral centres or other 
healthcare settings. Second, the controlled before and 
after study design is quasi- experimental and less robust 
than a randomised trial. It is possible that secular trends 
in practice outside of the pathway could have impacted 
on duration of stay. However, our stratified analysis 
demonstrated that the observed reductions in duration 
of stay were confined to those patients where care would 
have been modified by the pathway. Nevertheless, we are 
unable to adjust for unmeasured confounding including 
changes in clinical practice during the study period which 
may have contributed to differing clinical characteristics 
in the standard care and intervention groups. Third, all 
clinical decisions were made by the attending clinician 
and therefore not all patients identified as low risk may 
have been discharged according to our protocol. This 
may have introduced bias, however our findings are an 
accurate reflection of clinical practice where judgements 
are made according to many factors and care pathways 
are not always followed. Fourth, we did not adjudicate the 
diagnosis of myocardial infarction or evaluate diagnostic 
performance. For clinical outcomes, we used routinely 
collected data. Although this may introduce misclassifi-
cation, given the same approach was used during both 
the standard care and implementation phases of our 
study it is unlikely to have introduced bias. Fifth, while 
most patients who had an admission cardiac troponin 
requested would be in the context of suspected acute 
coronary syndrome, we are unable to exclude patients in 
whom troponin was requested for other clinical condi-
tions such as pulmonary embolus or acute heart failure. 
Finally, we used the hs- cTnT thresholds recommended 
by the manufacturer for use in the UK and the rest of 
the world, but we are aware the limit of detection varies 
across different platforms and that the 99th centile 
recommended for use by the US Food and Drug Admin-
istration (USFDA) is higher. Furthermore, the USFDA 
does not permit the reporting of concentration below 
6 ng/L. While the threshold of 5 ng/L used here is likely 
to have similar effectiveness and safety as using other 
Roche platforms, we cannot directly inform the safety of 
implementing this approach using the USFDA thresh-
olds.
CONCLUSION
In patients with suspected acute coronary syndrome, 
implementing an early rule- out pathway, using an hs- cTnT 
concentration of <5 ng/L at presentation for risk stratifi-
cation, reduced the duration of stay in hospital without 
compromising safety. The adoption of this approach in 
clinical practice could have major benefits for patients 
and healthcare providers.
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